For 20 years and throughout its research programmes, the European Union has supported the entire innovation chain for gene transfer and gene therapy. The fruits of this investment are ripening as gene therapy products are reaching the European market and as clinical trials are demonstrating the safety of this approach to treat previously untreatable diseases.
Get full access to this article
View all access options for this article.
References
1.
European Gene Vector Database and Repository (EGDR). European Commission. Contract 98.0190. www.aramis.admin.ch/Texte/?ProjectID=6927 (last accessed June19, 2017).
2.
VeluT. Gene transfer and therapy in Europe: research, development and clinical trials. European Commission. 1996. Contract ETD/94/B5-3000/MI/11.
3.
MartinPA, CrowtherS, CorneliussenF, et al.Gene therapy in Europe: exploitation and commercial development. European Commission. 2000. Contract BIO4-98-0380.
4.
Wiley. Gene Therapy Clinical Trials Worldwide, provided by the Journal of Gene Medicine. www.wiley.com//legacy/wileychi/genmed/clinical/ (last accessed June19, 2017).
5.
GancbergD, Draghia-AkliR. Gene and cell therapy funding opportunities in Horizon 2020: an overview for 2014–2015. Hum Gene Ther, 2014; 25:175–177.
6.
Abou-El-EneinM, ElsanhouryA, ReinkeP. Overcoming challenges facing advanced therapies in the EU market. Cell Stem Cell, 2016; 19:293–297.